334 related articles for article (PubMed ID: 24018532)
1. Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells.
Harimoto H; Shimizu M; Nakagawa Y; Nakatsuka K; Wakabayashi A; Sakamoto C; Takahashi H
Immunol Cell Biol; 2013 Oct; 91(9):545-55. PubMed ID: 24018532
[TBL] [Abstract][Full Text] [Related]
2. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
3. A combination of check-point blockade and α-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo.
Ishii K; Shimizu M; Kogo H; Negishi Y; Tamura H; Morita R; Takahashi H
Immunobiology; 2020 Jan; 225(1):151860. PubMed ID: 31812347
[TBL] [Abstract][Full Text] [Related]
4. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
5. In vivo priming of natural killer T cells by dendritic cells pulsed with hepatoma-derived acid-eluted substances.
Ishii R; Shimizu M; Nakagawa Y; Shimizu K; Tanaka S; Takahashi H
Cancer Immunol Immunother; 2004 May; 53(5):383-90. PubMed ID: 14624311
[TBL] [Abstract][Full Text] [Related]
6. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
7. Purification of antigenic peptide from murine hepatoma cells recognized by Class-I major histocompatibility complex molecule-restricted cytotoxic T-lymphocytes induced with B7-1-gene-transfected hepatoma cells.
Nakatsuka K; Sugiyama H; Nakagawa Y; Takahashi H
J Hepatol; 1999 Jun; 30(6):1119-29. PubMed ID: 10406192
[TBL] [Abstract][Full Text] [Related]
8. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes.
Kamphorst AO; Guermonprez P; Dudziak D; Nussenzweig MC
J Immunol; 2010 Sep; 185(6):3426-35. PubMed ID: 20729332
[TBL] [Abstract][Full Text] [Related]
9. Analysis of DC Functions Using CD205-DTR Knock-In Mice.
Fukaya T; Takagi H; Uto T; Arimura K; Sato K
Methods Mol Biol; 2016; 1423():291-308. PubMed ID: 27142025
[TBL] [Abstract][Full Text] [Related]
10. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
11. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
12. Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties.
Miller G; Pillarisetty VG; Shah AB; Lahrs S; DeMatteo RP
J Immunol; 2003 Apr; 170(7):3554-64. PubMed ID: 12646617
[TBL] [Abstract][Full Text] [Related]
13. Induction of tumor-specific CD8
Tomita Y; Watanabe E; Shimizu M; Negishi Y; Kondo Y; Takahashi H
Cancer Immunol Immunother; 2019 Oct; 68(10):1605-1619. PubMed ID: 31531696
[TBL] [Abstract][Full Text] [Related]
14. Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.
Moriya K; Wakabayashi A; Shimizu M; Tamura H; Dan K; Takahashi H
Cancer Immunol Immunother; 2010 Jul; 59(7):1083-95. PubMed ID: 20221597
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitory effects of human AFP-derived peptide-pulsed dendritic cells on mouse hepatocellular carcinoma].
Pang XH; Chen MS; Jia WH; Zhou XX
Ai Zheng; 2008 Dec; 27(12):1233-8. PubMed ID: 19079985
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
[TBL] [Abstract][Full Text] [Related]
17. Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.
Tosi D; Valenti R; Cova A; Sovena G; Huber V; Pilla L; Arienti F; Belardelli F; Parmiani G; Rivoltini L
J Immunol; 2004 May; 172(9):5363-70. PubMed ID: 15100276
[TBL] [Abstract][Full Text] [Related]
18. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
19. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
20. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
